undamentalytics Newsletter
Sign in

Lenz Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Lenz Therapeutics, Inc. had total assets of $306m, total liabilities of $21.5m and shareholders' equity of $284m. It held $25.2m in cash against $0 of debt: net cash of $25.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents202524
Receivables000
Inventory034
Total current assets212301233
Total assets215306237
Accounts payable447
Deferred revenue (current)—01
Total current liabilities102117
Total debt000
Total liabilities112217
Shareholders' equity204284219
Net debt (negative = net cash)−20−25−24
Shares outstanding—31m31m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: JANX vs LENZLENZ vs SCYXCELU vs LENZ

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lenz Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lenz Therapeutics, Inc.